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ABSTRACT
Purpose: In China, efforts are underway to respond to
rapidly increasing rates of heart disease and stroke. Yet
the epidemiology of cardiovascular disease in China
may be different from that of other populations. Thus,
there is a critical need for population-based studies
that provide insight into the risk factors, incidence and
outcomes of cardiovascular disease in China. The
Qingdao Port Cardiovascular Health Study is designed
to investigate the burden of cardiovascular disease and
the sociodemographic, biological, environmental and
clinical risk factors associated with disease onset and
outcomes.
Participants: For this study, from 2000 through
2013, 32 404 employees aged 18 years or older were
recruited from the Qingdao Port Group in China,
contributing 221 923 annual health assessments. The
mean age at recruitment was 43.4 (SD=12.9); 79%
were male. In this ongoing study, annual health
assessments, governed by extensive quality control
mechanisms, include a questionnaire (capturing
demographic and employment information, medical
history, medication use, health behaviours and health
outcomes), physical examination, ECG, and blood and
urine analysis. Additional non-annual assessments
include an X-ray, echocardiogram and carotid
ultrasound; bio-samples will be collected for future
genetic and proteomic analyses. Cardiovascular
outcomes are accessed via self-report and are actively
being verified with medical insurance claims; efforts
are underway to adjudicate outcomes with hospital
medical records.
Findings to date: Early findings reveal a significant
increase in cardiovascular risk factors from 2000 to
2010 (hypertension: 26.4–39.4%; diabetes: 3.3–8.9%;
hyperlipidaemia: 5.0–33.6%; body mass index
>28 m/kg2: 14.1–18.6%).
Future Plans: We aim to generate novel insights
about the epidemiology and outcomes of
cardiovascular disease in China, with specific
emphasis on the potentially unique risk factor
profiles of this Chinese population. Knowledge
generated will be disseminated in the peer-
reviewed literature, and will inform population-
based strategies to improve cardiovascular health
in China.
Trial registration number: NCT02329886.
INTRODUCTION
Epidemiological studies are the cornerstone
for understanding cardiovascular risk factors
and disease. Decades of research extending
from the Framingham Heart Study and other
cardiovascular studies (eg, Atherosclerosis
Risk in Communities Study) provide insight
into the complex interplay between biology,
behaviour, environment and genes, on the
risk of cardiovascular disease (CVD) and
stroke.1–4 However, existing studies of the epi-
demiology of CVD may have limited rele-
vance to other populations, particularly in
countries with different health behaviours
and environments.
The relationships between risk factors and
CVD outcomes differ between populations.
As demonstrated in the WHO Multinational
Monitoring of Trends and Determinants in
Cardiovascular Disease (MONICA) Project,
along with other studies, metabolic, dietary
and other lifestyle factors do not consistently
portend the same cardiovascular risk across
populations.5–11 The graded relationship
between higher cholesterol levels and mortal-
ity from coronary heart disease varies among
Western countries12 and may differ in
China.13 14 Studies also demonstrate
Strengths and limitations of this study
▪ This is a prospective cohort study conducted for
over 10 years.
▪ The study collected a variety of information
including cardiovascular risk factors, clinical out-
comes and bio-samples, allowing a wide ranging
assessment of risk factors and genetic factors
related to cardiovascular disease onset and car-
diovascular outcomes.
▪ Findings will have broad implications for China’s
workforce and for employer-based healthcare.
▪ Participants are limited to a single company and
may not be representative of the larger popula-
tion of China.
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differences in the epidemiology of stroke, with the slope
of the relationship between blood pressure and stroke
steeper among Asian populations as compared with
Australian populations,15 and haemorrhagic stroke
occurring more frequently in Chinese populations than
in Western populations.16 In summary, the epidemiology
of heart disease and stroke in China, and its associated
risk factors, may be different from that of other popula-
tions, and thus may have different implications for inter-
vention and prognosis. Understanding potential
differences in the epidemiology and outcomes of CVD
in China requires population-based studies.
Well-conducted, population-based prospective studies
focused on CVD are critical, especially as China is
experiencing remarkable changes in the cardiovascular
risk of its population.17–20 Similar to other developing
countries undergoing an epidemiological transition,
there has been a dramatic rise in the prevalence of non-
communicable diseases such as CVD.13 21Approximately
1 in 5 Chinese adults aged 18 years or older (approxi-
mately 230 million people) have CVD, the prevalence of
which is expected to double in the next decade.22 23
Beyond the expected rise in CVD associated with longer
life expectancy,24 other factors such as urbanisation,25
environmental pollutants26–28 and sociocultural shifts,29
have been associated with the increasing prevalence of
obesity,30 hypertension,31 diabetes32 and smoking,33
though their relationship with CVD in China has not
been well described.34 35 To date, there are few contem-
porary, prospective, population-based studies to identify
factors associated with heart disease and stroke in the
Chinese population.36 37
Accordingly, the Qingdao Port Group and its affiliated
hospital, Qingdao Fuwai Hospital, established the
Qingdao Port Cardiovascular Health Study in 2000, a
prospective cohort study of employees of the Group,
with the aims of monitoring the incidence of CVD and
associated risk factors, and identifying risk factors asso-
ciated with the incidence of CVD and cardiovascular
outcomes. Knowledge gained from this study will be
used to guide China’s efforts in preventing and man-
aging heart disease and stroke. In this paper, we describe
the design, cohort and investigational priorities of the
Qingdao Port Cardiovascular Health Study.
COHORT DESCRIPTION
Study design and investigational priorities
The Qingdao Port Cardiovascular Health Study was
started in 2000. The study is designed to monitor CVD
trends and to understand risk factors contributing to
chronic conditions with a focus on heart disease and
stroke.38 39 Specifically, the main investigational prior-
ities are: (1) surveillance of cardiovascular risk factors,
disease and outcomes; (2) investigation of sociocultural,
biological, behavioural, social and environmental factors
on work productivity, CVD onset and CVD health out-
comes; (3) development and validation of risk models to
predict cardiovascular events; and (4) genetic and prote-
omic analysis of biological samples to elucidate disease
mechanisms and inherited risk profiles.
Setting, recruitment and eligibility
The Qingdao Port Group of the Shandong province in
China is one of the oldest and largest shipping and trade
companies in the world (figure 1). The workforce is
diverse, with administrative personnel, technical personnel
(eg, pilots, computer analysts and information technology
Figure 1 Examination sites for
the Qingdao Port Cardiovascular
Health Study.
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specialists, police, teachers, physicians, nurses and other
hospitals staff), production operators, ship workers, dock-
workers and drivers. Among them, ship workers and dock-
workers account for the majority of all staff.
The company contributes to each employee’s health
insurance plan, which is administered by the Qingdao
Medical Insurance Bureau. The plan covers annual
health assessments, on-site ambulatory medical care and
coverage of inpatient services rendered at the Qingdao
Fuwai Hospital—the local hospital and partner in this
study—as well as other public hospitals in Qingdao city.
All employees aged 18 years or older, who present for an
annual health assessment, are eligible for study partici-
pation. The only exclusion is workers who are migrant,
as they are not covered by the local health insurance
and do not receive annual health examinations, effect-
ively rejecting them from study participation.
Prior to 2013, employees were verbally asked to partici-
pate. Since then, however, employees sign an informed
consent document prior to enrolment (see online sup-
plementary appendix 1: translated informed consent
document). Among the employees who present for a
health assessment, almost all (98%) agreed to partici-
pate in the study. At each annual visit, employees renew
their agreement to participate. Participants are informed
that the data are confidential.
The annual health assessments, offered at the three work
sites, serve as the platform for data collection. The organ-
isational structure for the study is presented in figure 2.
Health assessment components
Annual health assessments, which are performed by 35
trained physicians and nurses, consist of a questionnaire,
physical examination, ECG, laboratory testing and
bio-sampling. In 2013, echocardiography and carotid
ultrasound were additionally performed, and bio-
samples were collected for future analysis. Currently,
there are 466 unique variables summarised by domain
in online supplementary appendix 2.
Questionnaire
A standardised questionnaire is administered by trained
personnel during a face-to-face annual health assess-
ment (see online supplementary appendix 3). Questions
are adapted from prior epidemiological studies40 and,
when available, questionnaires validated in Chinese are
used.41 The following domains are assessed: demograph-
ics (eg, income, education, family structure); personal
medical history (eg, medical history, medication use and
adherence); family history; health behaviours (eg, nutri-
tional intake; physical activity;42 smoking; alcohol use/
abuse); healthcare utilisation (eg, hospitalisations; use of
traditional Chinese medicine); menopause (including
hormone use); emotional health (eg, anxiety, stress);
and employment structure (eg, physical labour;
shift-work).
Physical examination
A detailed, comprehensive physical examination is con-
ducted at baseline by trained medical staff. Nurses
measure height, weight, waist circumference, hip circum-
ference, blood pressure and heart rate. Physicians
perform a detailed eye and ear examination, dental
assessment, thyroid palpation, cardiopulmonary auscul-
tation and abdominal examination. Nurses and physi-
cians follow standardised protocols for measurement
and examination. Height (cm), weight (kg), and waste
and hip circumferences are measured using sonographic
Figure 2 Organisational
structure of the Qingdao Port
Cardiovascular Health Study.
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technology (Ultrasound Height & Weight Machine,
TCS-160D-W/H, Shenzhen Sonka Electronic Technology
Co, Ltd, Guangdong, China), averaged to the nearest
0.1 unit. Instruments are calibrated weekly with
phantom mannequins. Blood pressure and heart rate
are measured after the patient has been seated for
5 min, using a calibrated electronic sphygmomanometer.
Blood pressure measurement is performed by placing
the cuff on the dominant arm, at the level of the heart,
and taking the average of three measurements spaced
1 min apart. Heart rate is recorded contemporaneously
with each blood pressure measurement.
Laboratory tests
Venipuncture, performed by trained nurses, is obtained
annually. Some blood chemistries are repeated each year
(eg, fasting glucose, lipid profile, creatinine). Tests per-
formed intermittently include liver and thyroid function.
Bio-samples for future analysis
Since 2013, participants have been invited to submit bio-
samples, including blood, urine and saliva samples, for
storage, to be used for future DNA, RNA and biochem-
ical analysis. Over 90% of study participants have con-
sented to date. Whole blood samples are drawn into
EDTA, serum gel, heparin lithium and Tempus blood
RNA tubes (Applied Biosystems, Foster City, California,
USA) for future gene expression analysis. When stored
in Tempus tubes at −80°C, the whole blood RNA retains
high integrity and purity for over a 6-year period.43 To
collect saliva, participants are asked to chew a cotton roll
for 45 s; the cotton roll is placed into a Salivette tube
(Sarstedt AG & Co, Nümbrecht, Germany). Within 24 h,
trained nurses centrifuge blood and saliva samples, and
divide and transfer the samples into cryovials, according
to standard protocol. Urine is transferred directly into
cryovials. All samples are immediately stored at −80°C,
and are transported to Fuwai Hospital, National Center
for Cardiovascular Diseases (NCCD), for long-term
storage, within 2 months.
Additional testing
ECG is performed every year. Additionally, specific car-
diovascular screening tests were conducted during differ-
ent years including: chest X-ray, echocardiogram and
carotid ultrasound. All imaging tests are conducted by
certified technologists in accordance with standards set
forth by the Ministry of Health.
Follow-up
Follow-up health assessments are performed annually.
While the employee population is dynamic, among the
32 404 study participants from 2000 to 2013, more than
half (18 111; 55.9%) have 5 or more years of follow-up;
11 537 (35.6%) participants have 10 or more years of
follow-up (figure 3). Of the original cohort of 11 201
people who started in 2000, 7433 were not participating
in annual follow-up as of 2013. For example, among
22 128 study participants who enrolled between 2000
and 2010, 3280 (14.8%) had no follow-up visit after 2011
and before the end of the 2013 measurement period.
These employees may have left the company or declined
further participation; it is also possible, though less
likely, that they missed three consecutive visits and will
return in 2014. Distinguishing individuals with inter-
rupted visits from permanent drop-outs is a goal for the
future (table 1).
The components of the follow-up visit are the same as
the baseline assessment and include a face-to-face inter-
view, physical examination, laboratory testing and
imaging examinations specified for that year. New parti-
cipants are recruited each year (figure 4) and, since
Figure 3 Distribution of frequency of study participant follow-up.
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2003, participants have or are being followed into retire-
ment, up until death. In China, the statutory retirement
age for general workers is 60 years for men and 50–
55 years for women, depending on their job position.
Among heavy labourers, the retirement age is 55 years
for men and 45 years for women. Senior professionals
may work until the age of 65–70 years. Since 2003, retir-
ees account for approximately one-quarter of all annual
health assessments each year, with approximately 7000
retirees in the study.
Outcomes
The following cardiovascular outcomes are collected:
unstable angina; acute myocardial infarction; revasculari-
sation with either percutaneous coronary intervention
or coronary artery bypass grafting; heart failure; stroke;
and all-cause death. As part of the annual health
questionnaire, participants are asked to report informa-
tion on newly diagnosed diseases, hospitalisations and
treatments that occurred in the previous year.
Self-reported health outcomes are actively being linked
with medical claims data; since all employees have the
same insurance plan, complete insurance claims data
are available for all years except 2000 and 2001, years in
which not all employees were insured with the same
plan. Additionally, since 2013, medical claims have been
linked with health assessment data every 3 months, inde-
pendent of whether participants self-reported a clinical
outcome. From the medical claims, the following infor-
mation is abstracted: admission date, discharge date, dis-
charge diagnoses and corresponding International
Classification of Disease (ICD) codes; and discharge
status. Deaths are monitored by the insurance plan and
shared with the Qingdao Port Company and study
Table1 Follow-up among study participants
Non-returning participants
Description Total cohort Returning participants N Percent
2000 to 2001–2013 11 201 11 201 0 0.00
2000–2001 to 2002–2013 12 363 12 260 103 0.83
2000–2002 to 2003–2013 13 474 13 291 183 1.36
2000–2003 to 2004–2013 15 849 15 212 637 4.02
2000–2005 to 2006–2013 16 614 15 637 977 5.88
2000–2006 to 2007–2013 17 136 15 838 1298 7.57
2000–2007 to 2008–2013 17 963 16 263 1700 9.46
2000–2008 to 2009–2013 18 947 16 833 2114 11.16
2000–2009 to 2010–2013 20 221 17 476 2745 13.57
2000–2010 to 2011–2013 22 128 18 848 3280 14.82
2000–2011 to 2012–2013 22 670 18 775 3895 17.18
2000–2012 to 2013 24 636 18 521 6115 24.82
Figure 4 Distribution of new and returning study participants per year.
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group, which prompts the collection of death certificates
and autopsy reports to elucidate the cause of death.
Hospital medical records are also assessed to verify cause
of death. If hospitalisation records or other supportive
records are not available, interviews with the person’s
relatives and physicians are conducted to acquire the
date and cause of death.
Efforts are underway to adjudicate a subset of out-
comes using hospital medical records. In 2013, 855 par-
ticipants reported hospitalisations, 300 of which were
reported to have occurred at Qingdao Fuwai Hospital,
all of which were verified. Among patients who reported
being hospitalised outside of Qingdao Fuwai Hospital
(n=555), medical records from 246 participants were
obtained. These records came directly from participants,
though there are efforts to develop a process that will
enable the direct collection of study participants’
medical records from outside hospitals. Consistent with
other cardiovascular research protocols,44 adjudicators
will review the clinical diagnosis and the claims-based
ICD code, and compare them with self-reported data.
Discrepancies between the medical record and claims
data are resolved by the research guidance committee in
Fuwai Hospital, NCCD.
Quality assurance and control
All research staff participate in 2 days of intensive train-
ing focused on administering the questionnaire and
learning the protocols for blood pressure measurements,
anthropometry, blood collection and sample processing,
ECG and data entry. Further operational training is con-
ducted at the study sites. Each year, all equipment,
including the biochemical analyser, ultrasound machine,
X-ray machine, electronic sphygmomanometer and
ultrasound stadiometers are tested and calibrated by the
Qingdao Institute of Measurement and Testing and the
Qingdao Institute of Weighing Apparatus Management;
annual calibration certificates by these two institutes are
required. The validity of all measurements is checked
monthly by examination of data outliers and missing
fields. Additionally, site monitoring is conducted by two
trained research staff members from Fuwai Hospital,
NCCD, every 3–6 months, assessing: (1) the complete-
ness of the documentation and (2) fidelity to protocol
for recruitment, health screening, physical examination,
and sample collection and processing. Finally, annual
meetings are held to discuss problems with measure-
ment and data entry, and to optimise study processes.
To improve the validity and reliability of the measure-
ment of cardiovascular risk factors, questions were
adapted from prior epidemiological studies in China,
such as questions assessing smoking and dietary pat-
terns.40 In 2013, questionnaires that were previously vali-
dated in Chinese were incorporated. We used the
Alcohol Use Disorders Identification Test (AUDIT)
questionnaire to identify persons with hazardous and
harmful patterns of alcohol consumption,41 the
International Physical Activity Questionnaire (IPAQ) to
assess physical activity42 and the EuroQoL (EQ-5D) to
measure health status.45
The definition of hyperlipidaemia changed from
earlier years in accordance with the level of data avail-
able. For example, in some prior years, no blood lipid
tests were performed; in these years, only self-report and
medication use were used to define hyperlipidaemia.
Since 2010, hyperlipidaemia has been defined as: either
self-report of high cholesterol or dyslipidaemia (either:
total cholesterol ≥5.2 mmol/L or low-density lipoprotein
≥3.4 mmol/L or high-density lipoprotein <1.0 mmol/L
or triglycerides ≥1.7 mmol/L) or use of a lipid-lowering
medication.
From 2000 to 2012, data were collected on paper and
double-entered by two different researchers into a
computer-based system, to reduce error. Since 2013,
results from the questionnaire, physical examination,
laboratory testing and other examinations have been col-
lected electronically with an internet-based data manage-
ment system developed specifically for the study. To
increase the validity and reliability of the data, this
system includes predefined data formats, predetermined
data ranges for quantitative data, and required fields.
After research personnel enter the data, internal data
checks are performed to confirm that the data are cor-
rectly entered. Finally, prior to the beginning of each
measurement year, all personal information is verified
(name, sex, ID number, work ID, company, department,
contact telephone number and address); these steps
improve the accuracy of participants’ information,
decrease the duration of face-to-face interview time and
facilitate linkage with medical insurance records.
Data security and management
All data are treated as protected health information, and
are securely stored in an encrypted and password-
protected database. Laptops are password protected,
and all research personnel have individual passwords to
login to the system. All data between the three sites are
independent, which means research personnel only
have access to the data collected at their own site.
All source data, including questionnaires, health
assessment results, hospitalisation and clinical medical
records, are securely stored in the three clinic sites of
the Qingdao Fuwai Hospital. The electronic version of
the files as well as the image files of ECG and chest
X-rays are securely stored on the servers of Qingdao
Fuwai Hospital. The Research Guidance Committee,
comprised of investigators from the Fuwai Hospital,
NCCD, and Qingdao Fuwai Hospital, make the ultimate
decisions on the usage of the data, governed by institu-
tional review board approval.
Cohort
From 2000 through 2013, a total of 32 404 study partici-
pants contributed 221 923 health assessments. In this
cohort, the mean age was 43.4 (SD=12.9); 79% were
male, consistent with the demographics of the company.
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Participants ranged in occupation: loading/unloading
(9.7%); warehouse clerk (8.0%); ship crew (18.8%);
other shipping and dockworkers (29.9%); management
(19.9%); other (13.7%).
Findings to date
Table 2 compares cardiovascular risk factors across three
time periods (2000 to 2005 to 2010), demonstrating an
increased prevalence of hypertension (26.4% to 38.6%
to 39.4%) and diabetes (3.3% to 5.9% to 8.9%), respect-
ively. The 2005 estimates for hypertension and diabetes
are similar to those observed in the 2005 International
Collaborative Study of CVD in Asia (InterAsia).46 Rates
of hyperlipidaemia increased from 5% to 12.4% to
33.6% across study years; however, full blood lipid panels
were not conducted between 2001 and 2006. These rates
are lower than those observed in a meta-analysis in
which 41% of community-residing adults had
dyslipidaemia.47
Strengths and limitations
The Qingdao Port Cardiovascular Health Study is
uniquely positioned to measure disease incidence and
trends, characterise the complex relationships between
biology, environment, culture and behaviour with
disease onset, trajectories and outcomes, and ultimately
Table 2 Trends in characteristics of study participants (2000–2010)
2000 2005 2010
Description n Percent n Percent n Percent
Total participants 12 023 14 152 16 378
Retirees NA NA 3369 23.8 4594 28.1
Demographics
Age (mean; SD) 39 8.7 45 12.0 45 13.7
Gender
Male 9227 76.7 10 945 77.3 13 076 79.8
Female 2796 23.3 3207 22.7 3302 20.2
Cardiovascular profile
High blood pressure*
Yes 3176 26.4 5457 38.6 6451 39.4
Missing 0 0 4 <0.1 4 <0.1
Diabetes†
Yes 396 3.3 838 5.9 1458 8.9
Missing 0 0 0 0 4 <0.1
Hyperlipidaemia‡
Yes 600 5.0 1749 12.4 5499 33.6‡
Missing 0 0 565 4.0 4 <0.1
Acute myocardial infarction
Yes NA NA 66 0.5 128 0.8
50 0.4 301 1.8
Stroke
Yes 66 0.5 130 0.9 188 1.1
Missing 3 <0.1 49 0.4 320 2.0
Anthropometrics
Waist (cm)
Mean (SD) 81.6 11.2 83.9 9.6 86.6 12.3
Missing 0 0 292 2.1 215 1.3
BMI (cm/kg2)
Missing 25 0.2 277 2.0 190 1.2
Normal body weight (<24) 5852 48.7 5317 37.6 6313 38.6
Overweight (24 to <28) 4456 37.1 5972 42.2 6831 41.7
Obese (≥28) 1690 14.1 2586 18.3 3044 18.6
Systolic blood pressure
Missing 0 0 58 0.4 63 0.4
Mean (SD) 121 17.1 122 18.3 125 20.9
Diastolic blood pressure
Mean (SD) 80 12.1 82 11.6 82 11.2
*Self-report or mean blood pressure ≥140 systolic or ≥90 mm Hg diastolic or antihypertensive medication therapy.
†Self-report or fasting glucose ≥7.0 mmol/L or glucose-lowering medication.
‡Self-report or lipid-lowering therapy for year 2000; self-report only for year 2005; self-report or dyslipidaemia (either: total cholesterol
≥5.2 mmol/L or low-density lipoprotein ≥3.4 mmol/L or high-density lipoprotein <1.0 mmol/L or triglycerides ≥1.7 mmol/L) or lipid lowering
medication therapy for year 2010.
BMI, body mass index; NA, not available.
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inform the approach to CVD prevention and population
health, especially among China’s urban, working popula-
tion. Knowledge generated from the population of the
Qingdao Port Cardiovascular Health Study will have
broad implications for China’s workforce and for
employer-based healthcare, where large employers con-
tract with health systems to provide comprehensive
healthcare services to their employees, including health
screenings, outpatient medical care and inpatient ser-
vices. In 2006, approximately 160 million people (about
28% of the urban population) were covered by
employer-based health insurance.48 This study, which
aligns research objectives with current health challenges,
is embedded in the employer-based health services
model, and can thereby foster knowledge dissemination
and translation among such employers. Importantly, the
rigorous methodological design and health data collec-
tion, follow-up into retirement, and linkage of health
screening data with insurance claims and medical
records, will provide a rich opportunity to investigate
disease trajectories and outcomes, and inform
approaches to population-based healthcare delivery.
Other Chinese population-based studies, such as the
China National Diabetes and Metabolic Disorders Study
(2007–2008), while nationally representative, are cross-
sectional and less comprehensive.18 47 The Singapore
Chinese Health Study49 and the Chinese Health and
Retirement Longitudinal Study (CHARLS)50 provide
data on older populations, though they are not focused
on CVD and have limited follow-up data. To date, there
are no longitudinal, population-based cardiovascular
studies of the urban, working population of China. The
study is supported by the Fuwai Hospital, NCCD—a clin-
ical research group with longstanding expertise in stan-
dardised data abstraction, cataloguing and linkage,
ensuring excellent quality control, and organisation for
scientific investigation.51–53
There are some limitations to this study. The popula-
tion represents a single company and may not be repre-
sentative of the larger population of China. Additionally,
employed individuals may be healthier than the general
population, which may influence the relationship
between risk factors and disease onset. However, the
study subjects from the Qingdao Port Company are from
diverse sectors of the workplace; moreover, the data set
is rich with health behaviours and socioeconomic infor-
mation, which may account for variation in associations
within the population. The focus on an employee popu-
lation is consistent with new models of knowledge dis-
covery and health promotion.54 Additionally,
longitudinal follow-up of a stable population has the
advantage of allowing for insights into risk trajectories
and outcomes. Second, participants are recruited from
an annual health screening, and so we lack information
about employees who are eligible but do not participate
in the health screening. However, very few employees
decline participation; nonetheless, processes for collect-
ing this information are being developed. Related to
this, it is possible that, in some cases, responses to the
interview questions might be influenced by the partici-
pants’ perceptions that their answers might affect their
employment status. Third, the collection of outcomes
for any longitudinal study is a challenge. The current
mechanisms, including self-report and claims data of ser-
vices rendered through the Qingdao Medical Insurance
Bureau are already more advanced than most
population-based studies. In the first year of attempting
to obtain medical records, over half were successfully
obtained. Further efforts are needed to improve this pro-
portion, though this can be accomplished. Additionally,
the ascertainment of claims data allows for extensive util-
isation and cost analyses, which are unique to this study.
Collaboration
The Qingdao Port Cardiovascular Study is ongoing, with
increasing capacity to adjudicate cardiovascular out-
comes, enhancing self-reported outcomes with insurance
claims data and hospital medical records. The publica-
tions committee and data analytic centre are comprised
of researchers from the NCCD, Fuwai Hospital, Beijing,
and from Yale University—two institutions with a long-
standing partnership and commitment to improving car-
diovascular health in China. At this time, all research
will be conducted in collaboration with the study investi-
gators. Prospective collaborators are encouraged to
contact either JLu ( jiapeng.lu@fwoxford.org) or ESS
(Erica.spatz@yale.edu).
China’s unique position of being a low-income to
middle-income country with significant intellectual
resources—as well as shared goals between academic,
private and public domains—can provide important
lessons to the world on the effects of globalisation and
the tools needed to protect the health of the public.
Longitudinal, population-based studies play an import-
ant part in this learning. The Qingdao Port
Cardiovascular Health Study is designed to fill these
knowledge gaps, and to provide important insights for
the public and healthcare system at large.
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